Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,172
  • Shares Outstanding, K 54,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -294,230 K
  • EBIT $ -355 M
  • EBITDA $ -352 M
  • 60-Month Beta N/A
  • Price/Sales 10.42
  • Price/Cash Flow N/A
  • Price/Book 1.13

Options Overview Details

View History
  • Implied Volatility 157.16% ( +14.72%)
  • Historical Volatility 70.18%
  • IV Percentile 37%
  • IV Rank 18.37%
  • IV High 452.99% on 04/17/25
  • IV Low 90.59% on 05/22/25
  • Put/Call Vol Ratio 0.62
  • Today's Volume 21
  • Volume Avg (30-Day) 558
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 57,551
  • Open Int (30-Day) 57,269

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.11
  • Number of Estimates 4
  • High Estimate -0.87
  • Low Estimate -1.48
  • Prior Year -23.10
  • Growth Rate Est. (year over year) +95.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.76 +20.65%
on 06/24/25
3.71 -10.24%
on 07/14/25
+0.32 (+10.63%)
since 06/18/25
3-Month
2.76 +20.65%
on 06/24/25
6.18 -46.16%
on 05/19/25
-1.67 (-33.40%)
since 04/17/25
52-Week
2.76 +20.65%
on 06/24/25
13.50 -75.33%
on 07/23/24
-9.18 (-73.38%)
since 07/18/24

Most Recent Stories

More News
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc.

ALMS : 3.33 (-5.13%)
Alumis to Present at the Jefferies Global Healthcare Investor Conference

ALMS : 3.33 (-5.13%)
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

ALMS : 3.33 (-5.13%)
Alumis Completes Merger with ACELYRIN

ALMS : 3.33 (-5.13%)
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

ALMS : 3.33 (-5.13%)
Alumis Stockholders Approve Merger with ACELYRIN

SLRN : 2.27 (+1.79%)
ALMS : 3.33 (-5.13%)
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

SLRN : 2.27 (+1.79%)
ALMS : 3.33 (-5.13%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

SLRN : 2.27 (+1.79%)
ALMS : 3.33 (-5.13%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

SLRN : 2.27 (+1.79%)
ALMS : 3.33 (-5.13%)
Alumis and ACELYRIN Announce Amended Merger Agreement

SLRN : 2.27 (+1.79%)
ALMS : 3.33 (-5.13%)

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 3.81
2nd Resistance Point 3.70
1st Resistance Point 3.51
Last Price 3.33
1st Support Level 3.21
2nd Support Level 3.10
3rd Support Level 2.91

See More

52-Week High 13.50
Fibonacci 61.8% 9.40
Fibonacci 50% 8.13
Fibonacci 38.2% 6.86
Last Price 3.33
52-Week Low 2.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar